Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1997 Mar;14(3):259-66.
doi: 10.1023/a:1012029517394.

The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual

Affiliations
Review

The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual

A T Florence. Pharm Res. 1997 Mar.

Abstract

This mini-review covers some of the historical and recent arguments over the experimental evidence on the uptake by and translocation from the intestinal mucosa of microparticulates after oral administration. It is concluded that there is now no dispute over the fact that this is a normal occurrence. Particulate uptake does take place, not only via the M-cells in the Peyer's patches and the isolated follicles of the gut-associated lymphoid tissue, but also via the normal intestinal enterocytes. Factors affecting uptake include particle size, surface charge and hydrophobicity and the presence or absence of surface ligands. The covalent attachment of lectin or invasion molecules to the surface of carrier particles leads to greater systemic uptake. Whether or not the route can be utilized for the routine administration of therapeutic agents which are not normally absorbed from the gut is not yet proven. Many studies show that 2-3% of the ingested dose of submicron particles can be absorbed. The increasing diversity of carrier systems, which includes dendrimers and liposomes, needs to be exploited fully. More also must be learned about the inter- and intra-subject variability of lymphoid tissue so that appropriate selectivity can be achieved through the design of specific carriers.

PubMed Disclaimer

References

    1. Pharm Res. 1996 Feb;13(2):272-8 - PubMed
    1. Histochemistry. 1993 Dec;100(6):441-7 - PubMed
    1. Nature. 1985 Sep 19-25;317(6034):262-4 - PubMed
    1. Ann N Y Acad Sci. 1987;507:19-21 - PubMed
    1. J Drug Target. 1996;4(2):87-93 - PubMed

LinkOut - more resources